Aberrant energy metabolism and metabolic reprogramming play an important role in the initiation, progression, metastasis, and drug resistance of hematologic malignancies. This broadly includes mitochondrial energy metabolism, fatty acid synthesis, lipid droplets formation as well as other forms of metabolism. Moreover, metabolic reprogramming existing in the microenvironment of hematologic malignancies also increases the probability of resistance to anticancer therapies. Recurrence and refractory always exist in patients with hematologic malignancies who received FDA-approved drugs, so novel researches focus on new metabolic therapies alone or in combination with targeted therapy or chemotherapy drugs are imperative.
We aim to address the contribution of cellular metabolism on the progression of hematological malignancies and illustrate the signaling pathways controlling the cellular metabolism, by which identify new therapeutic targets and their targeted drugs. New metabolic therapies alone or in combination with targeted therapy or chemotherapy drugs would be of particular interest.
We would like to invite submissions of Original Research articles or Reviews on the progress and current understanding of cellular metabolism of hematologic malignancies, including preclinical research, clinical research, as well as genomics, proteomics, and metabolomics studies with in vivo or in vitro validation. Topics of interest include but are not limited to the following:
• The impact of new metabolic mechanisms supporting hematological malignancy metastases, immune escape, therapeutic resistance, as well as metabolic interactions between the tumor cells and the microenvironment.
• The effect of existing drugs or de novo drugs on cellular metabolism, alone or in combination with other drugs.
• In vivo studies evaluating metabolic therapies alone or in combination with other drugs.
• Novel technologies to study cellular metabolism. New single-cell analysis techniques are highly encouraged, which are beneficial for providing information regarding single-cell metabolism.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Aberrant energy metabolism and metabolic reprogramming play an important role in the initiation, progression, metastasis, and drug resistance of hematologic malignancies. This broadly includes mitochondrial energy metabolism, fatty acid synthesis, lipid droplets formation as well as other forms of metabolism. Moreover, metabolic reprogramming existing in the microenvironment of hematologic malignancies also increases the probability of resistance to anticancer therapies. Recurrence and refractory always exist in patients with hematologic malignancies who received FDA-approved drugs, so novel researches focus on new metabolic therapies alone or in combination with targeted therapy or chemotherapy drugs are imperative.
We aim to address the contribution of cellular metabolism on the progression of hematological malignancies and illustrate the signaling pathways controlling the cellular metabolism, by which identify new therapeutic targets and their targeted drugs. New metabolic therapies alone or in combination with targeted therapy or chemotherapy drugs would be of particular interest.
We would like to invite submissions of Original Research articles or Reviews on the progress and current understanding of cellular metabolism of hematologic malignancies, including preclinical research, clinical research, as well as genomics, proteomics, and metabolomics studies with in vivo or in vitro validation. Topics of interest include but are not limited to the following:
• The impact of new metabolic mechanisms supporting hematological malignancy metastases, immune escape, therapeutic resistance, as well as metabolic interactions between the tumor cells and the microenvironment.
• The effect of existing drugs or de novo drugs on cellular metabolism, alone or in combination with other drugs.
• In vivo studies evaluating metabolic therapies alone or in combination with other drugs.
• Novel technologies to study cellular metabolism. New single-cell analysis techniques are highly encouraged, which are beneficial for providing information regarding single-cell metabolism.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
